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Abstract
Diabetes impacts approximately 200 million people worldwide, of whom approximately 10% are affected by type 1 diabetes
(T1D). The application of genome-wide association studies (GWAS) has robustly revealed dozens of genetic contributors to
the pathogenesis of T1D, with the most recent meta-analysis identifying in excess of 40 loci. To identify additional genetic
loci for T1D susceptibility, we examined associations in the largest meta-analysis to date between the disease and ,2.54
million SNPs in a combined cohort of 9,934 cases and 16,956 controls. Targeted follow-up of 53 SNPs in 1,120 affected trios
uncovered three new loci associated with T1D that reached genome-wide significance. The most significantly associated
SNP (rs539514, P=5.66610
211) resides in an intronic region of the LMO7 (LIM domain only 7) gene on 13q22. The second
most significantly associated SNP (rs478222, P=3.50610
29) resides in an intronic region of the EFR3B (protein EFR3
homolog B) gene on 2p23; however, the region of linkage disequilibrium is approximately 800 kb and harbors additional
multiple genes, including NCOA1, C2orf79, CENPO, ADCY3, DNAJC27, POMC, and DNMT3A. The third most significantly
associated SNP (rs924043, P=8.06610
29) lies in an intergenic region on 6q27, where the region of association is
approximately 900 kb and harbors multiple genes including WDR27, C6orf120, PHF10, TCTE3, C6orf208, LOC154449, DLL1,
FAM120B, PSMB1, TBP, and PCD2. These latest associated regions add to the growing repertoire of gene networks
predisposing to T1D.
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Introduction
Diabetes impacts approximately 200 million people worldwide
[1], with microvascular and cardiovascular disease being the
primary complications. Approximately 10% of cases are type 1
diabetes (T1D) sufferers, with ,3% increase in the incidence of
T1D globally per year [2]. It is expected that the incidence is 40%
higher in 2010 than in 1998 [3].
T1D is a clear example of a complex trait that results from the
interplay between environmental and genetic factors. There are
PLoS Genetics | www.plosgenetics.org 1 September 2011 | Volume 7 | Issue 9 | e1002293many lines of evidence that there is a strong genetic component to
T1D, primarily due to the fact that T1D has high concordance
among monozygotic twins [4] and runs strongly in families,
together with a high sibling risk [5].
Prior to the era of GWAS, only five loci had been fully
established to be associated with T1D. However, the majority of
the other reported associations in the pre-GWAS era [6–8] remain
highly doubtful, where an initial report of association does not
hold up in subsequent replication attempts by other investigative
groups. This previous hazy picture of the genetics of T1D can be
put down to the use of the only methodologies that were available
at the time and which were much more limited than GWAS i.e.
the candidate gene approach (where genomic regions were studied
based on biological reasoning) and family-based linkage method-
ologies. Inconsistent findings can also be attributed to small sample
sizes i.e. when power is low the false discovery rate tends to be
high; GWAS per se has not improved consistency, rather it has
leveraged large, well powered sample sizes combined with sound
statistical analyses.
It has been long established that approximately half of the
genetic risk for T1D is conferred by the genomic region harboring
the HLA class II genes (primarily HLA-DRB1, -DQA1 and -DQB1
genes), which encode the highly polymorphic antigen-presenting
proteins. Other established loci prior to the application of GWAS
are the genes encoding insulin (INS) [9-12], cytotoxic T-
lymphocyte-associated protein 4 (CTLA4) [13–16], protein tyrosine
phosphatase, non-receptor type 22 (PTPN22) gene [17,18],
interleukin 2 receptor alpha (IL2RA) [19–21] and ubiquitin-
associated and SH3 domain-containing protein A (UBASH3A)
[22].
The application of genome wide association studies (GWAS) has
robustly revealed dozens of genetic contributors to T1D [23–29],
the results of which have largely been independently replicated
[30–36]. The most recently reported meta-analysis of this trait
identified in excess of forty loci [29], including 18 novel regions
plus confirmation of a number of loci uncovered through cross-
disease comparisons [34–36]. As such, the risks conferred by these
additional loci are relatively modest compared to the ‘low-hanging
fruit’ described in the first studies and could only be ultimately
uncovered when larger sample sizes were utilized.
We sought to expand further on this mode of analysis by
combining our cohort with all publically released genome wide
SNP datasets to identify additional loci contributing to the etiology
of T1D. Unfortunately, there is a relative paucity of control
genotype data in these publically available sources. To circumvent
this problem, we combined individual level data from each
available cohort and we then compared the cases with controls
from two sources. We next separated all the individual level data
into two groups, characterized by the type of genotyping platform
that was used to genotype the samples, which would later be
recombined using inverse-variance meta-analysis. The 6,523 cases
genotyped on an Illumina BeadChip included subjects from
McGill University, The Children’s Hospital of Philadelphia
(CHOP), The Diabetes Control and Complications Trial –
Epidemiology of Diabetes Interventions and Complications
(DCCT-EDIC) cohort, and the Type 1 Diabetes Genetics
Consortium (T1DGC), which in turn were compared with 6,648
similarly genotyped controls recruited at CHOP. The 3,411 cases
genotyped on Affymetrix arrays included subjects from the
Genetics of Kidneys in Diabetes Study (GoKinD) and the
Wellcome Trust Cases Control Consortium (WTCCC) that were
then compared with 10,308 similarly genotyped controls,
including being derived from non-autoimmune disease related
cases from the WTCCC, as well as from the British 1958 Birth
Cohort and the UK National Blood Service [24].
Results
We compared the power of our meta-analysis to that of the
previous largest meta-analysis to date. We have more than double
the power of the Barrett et al. meta-analysis to find variants with a
relative risk of 1.2 and approximately three times the power to
detect variants with a relative risk of 1.1 [29] (Figure S1).
We used principal components analysis (PCA) [37] in order to
minimize the potential impact of population stratification in our
case/control sample sets. Eigenstrat 3.0 was employed to remove
outliers and to subsequently calculate the principal components in
the Illumina and Affymetrix assigned groups separately. The
Author Summary
Despite the fact that there is clearly a large genetic
component to type 1 diabetes (T1D), uncovering the genes
contributing to this disease has proven challenging. Howev-
er, in the past three years there has been relatively major
progress in this regard, with advances in genetic screening
technologies allowing investigators to scan the genome for
variants conferring risk for disease without prior hypotheses.
Such genome-wide association studies have revealed
multiple regions of the genome to be robustly and con-
sistently associated with T1D. More recent findings have
been a consequence of combining of multiple datasets from
independent investigators in meta-analyses, which have
morepowertopickupadditionalvariantscontributingtothe
trait. In the current study, we describe the largest meta-
analysis of T1D genome-wide genotyped datasets to date,
which combines six largestudies. As a consequence, we have
uncovered three new signals residing at the chromosomal
locations 13q22, 2p23, and 6q27, which went on to be
replicated in independent sample sets. These latest associ-
ated regions addto the growing repertoire of gene networks
predisposing to T1D.
Figure 1. QQ-plot of all previously unassociated regions in the
combined meta-analysis discovery cohort.
doi:10.1371/journal.pgen.1002293.g001
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regression, using the software PLINK [38], to compute the P-
values, betas and standard errors which were combined in our
fixed effects inverse variance meta-analysis. After controlling for
population stratification, the l in the Affymetrix and Illumina
cohorts was 1.11 and 1.17, respectively (see Figure 1 for Q-Q plot).
A full description of the correlation of each eigenvector with
known continental ancestry appears in Text S1. Mach was used to
impute ,2.54 million SNPs, including HapMap Phase 2 SNPs in
the Illumina and Affymetrix datasets in order for the statistics to be
uniform and amenable to being combined [39]. Results from the
meta-analysis of this resulting ‘discovery’ cohort are shown Table 1
and graphically in Figure 2.
53 SNPs were brought forward to the replication stage based on
satisfying the following criteria; however one of these SNPs
consistently failed genotyping in the replication effort. The most
significantly associated SNP at a given locus if the meta-analysis
P-value was less than 1610
25 (an independent locus was defined
as a region for a given focal SNP, where we extended the region in
both directions until either 250 kb had been traversed or until
reaching another SNP with P,10
25), the Cochran’s Q statistic
P-value was greater than 0.05 and the locus had not been already
reported from a previous GWAS of T1D. A table outlining the
results for all previously described T1D associated SNPs plus our
strongest associations for known regions associated with the disease
are shown in Table 2 and Table S1, respectively. The replication
cohort consisted of additional T1D affected trios from the T1DGC
and McGill which had not been part of the original discovery
cohort. The replication cohort was genotyped using the Sequenom
iPLEX system and the results were analyzed using the transmis-
sion disequilibrium test in PLINK. Results for both the discovery
and replication cohorts for the six SNPs that replicated with
P#0.05 are shown in Table 1 (the full outcomes for all SNPs tested
are in Table S2).
We combined the ‘discovery’ and ‘replication’ meta-analysis
P-values using Fisher’s combined P-value method implemented in
Haploview, comparable to what has been previously employed
by others [40]. Three of the SNPs, namely rs539514, rs478222
and rs924043, had combined P-values ,5610
28, the statistical
threshold for genome wide significance, while the remaining three,
namely rs550448, rs12679857 and rs6547853, failed to reach this
bar but were suggestive of association as the alleles yielded both a
consistent direction of effect and P-values ,0.05 in the replication
cohort. These two categories of outcome are summarized in
Table 1; in addition, these six SNPs were further investigated with
respect to adjustments of the discovery and met-analysis P-values
based on the lambdas of each respective cohort (Table S3).
Discussion
We have carried out the largest meta-analysis of genome wide
genotyped datasets for T1D to date. The replication of three loci
using the stratification-free TDT with minimal Mendelian error
clearly indicates that they are not false positives due to artifacts
such as uncorrected systematic error from stratification or
genotyping bias.
The most significantly associated SNP (rs539514, P=
5.66610
211) resides in an intronic region of the LMO7 (LIM
domain only 7) gene on 13q22. We investigated the associated
region using LocusZoom [41] and determined that it is the only
gene residing within the block of linkage disequilibrium harboring
the signal (Figure S3). Regional plots showing P-values, linkage
disequilibrium, and recombination rate for all SNPs in Table 1 are
outlined in the Figures S2, S3, S4, S5, S6, S7. LMO7 encodes a
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homology domain, a PDZ domain and a LIM domain. There are
multiple LMO7 isoforms already known but their full nature and
the actual extent of different isoforms remains unclear [42]. Mice
with homozygous deletions of LMO7 display retinal, muscular, and
growth retardation [43]. Although the function of LMO7 doesn’t
clearly relate to the etiology of T1D, LMO7 is expressed in
pancreatic islets and thus is a possible biological candidate at this
locus [44]; however it should be noted that the retinal, muscular
development and islet patterns are a key element in Emery-
Dreifuss Muscular Dystrophy, caused by mutations in LMO7 [45],
but bears very little similarity to T1D.
The second most significantly associated SNP (rs478222,
P=3.50610
29) resides in an intronic region of the EFR3B
(protein EFR3 homolog B) gene on 2p23; however the region of
linkage disequilibrium is approximately 800 kb and harbors
additional multiple genes, including 3NCOA1, C2orf79, CENPO,
ADCY3, DNAJC27, POMC, and DNMT3A. (Figure S2). A previous
meta-analysis of a subset of the data used in this current study
found suggestive association with T1D in the same LD block with
the independent SNP, rs2165738(r
2=0.115), but did not achieve
genome wide significance at that time (P=3.65610
26) [27];
however, we only found modest evidence of association with
rs2165738 (P=4.78610
23) in our discovery cohort. There has
also been association to inflammatory bowel disease [46] height
[47,48] and BMI [49] reported at this locus, where in both cases
the risk allele for increased height or BMI was protective for T1D
risk.
The third most significantly associated SNP (rs924043,
P=8.06 610
29)l i e si na ni n t e r g e n i cr e g i o no n6 q 2 7 ,w h e r et h e
region of association is approximately 900 kb and harbors multiple
genes including WDR27, C6orf120, PHF10, TCTE3, C6orf208,
LOC154449, DLL1, FAM120B, PSMB1, TBP and PCD2 (Figure
S5). In addition, despite not reaching the bar for genome wide
significance, we did observe evidence for association at three
additional loci (Table 1) containing the candidate genes
LOC100128081, TNFRSF11B and FOSL2. Of these, it is notable
that TNFRSF11B is a strongly associated locus with bone mineral
density, also as a consequence of GWAS [50,51]. In addition, the
locusharboring LOC100128081 has also been reported in the context
of a GWAS of SLE [52]. Further work will be required to fully
validate the role of these particular loci in the pathogenesis of T1D.
The Barrett et al. meta-analysis was able to use British controls
with British cases and American controls with American cases
[29]. We did not have the same control data to be able to make the
same comparisons. In the case of the Affymetrix analysis, some
American cases were analyzed with purely British controls and, in
the case of the Illumina analysis, some British cases with purely
American controls. As such, we were forced to make our
corrections using eigenvectors as covariates in our analysis; this
will have the effect of modestly weakening the level of significance
for associations that vary in allele frequency between the cases and
controls, as now the case and controls will both vary with the
eigenvectors to some degree. This in effect will make our analysis
overly conservative with estimating the true effect of a SNP, and in
fact every SNP that had a P-value less than 0.05 in the replication
set did indeed have a greater effect than that which was estimated
from the discovery set.
In summary, we provide convincing evidence for the existence
of three additional loci associated with the T1D, adding to the
repertoire of over 50 loci already demonstrated to be associated
with the disease.
Materials and Methods
Ethical statement
The study was approved by the institutional review board and
the ethics committee of each institution. Written informed consent
Figure 2. Fixed effects meta-analysis P-values shown for each SNP in the combined meta-analyzed discovery cohort. SNPs are sorted
by chromosomal location. –log10(P-value) are shown, where the minimum P-value has been capped at 1610
210. Only the novel loci are indicated.
doi:10.1371/journal.pgen.1002293.g002
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PLoS Genetics | www.plosgenetics.org 4 September 2011 | Volume 7 | Issue 9 | e1002293Table 2. Discovery set P-values and odd ratios are shown for known T1D associated autosomal SNPs.
SNP CHR Position Gene/Region Effect Allele P-Value OR References
rs2476601 1 114179091 PTPN22 A 5.93E-80 1.96 [23,25,29]
rs2816316 1 190803436 RGS1 C 8.52E-04 0.89 [34]
rs3024505 1 205006527 IL10 A 2.09E-08 0.82 [29]
rs9653442 2 100191799 AFF3 C 5.89E-04 1.09 [25]
rs1990760 2 162832297 IFIH1 C 2.21E-08 0.87 [25,29]
rs7574865 2 191672878 STAT4 T 0.0544 1.06 [35]
rs3087243 2 204447164 CTLA4 A 1.42E-13 0.83 [27,29]
rs11711054 3 46320615 CCR5 G 0.0399 1.06 [34]
rs10517086 4 25694609 4p15.2 A 2.13E-04 1.10 [29]
rs4505848 4 123351942 IL2 G 2.26E-05 1.12 [27,29]
rs9268645 6 32516505 HLA G 3.94E-136 1.91 [24]
rs3757247 6 91014184 BACH2 T 1.62E-08 1.15 [27-29]
rs9388489 6 126740412 6q22.32 G 4.10E-06 1.12 [29]
rs10499194 6 138044330 TNFAIP3 T 7.92E-04 0.91 [35]
rs1738074 6 159385965 TAGAP T 9.48E-05 0.91 [34]
rs7804356 7 26858190 SKAP2 C 0.0101 0.93 [29]
rs4948088 7 50994688 7p12.1 NA NA NA [29]
rs10758593 9 4282083 GLIS3 A 1.18E-08 1.15 [28,29]
rs12251307 10 6163501 IL2RA T 1.22E-08 0.79 [27,29]
rs11258747 10 6512897 PRKCQ T 2.24E-05 1.13 [27,29]
rs10509540 10 90013013 10q23.31 C 2.83E-06 0.88 [29]
rs3741208 11 2126350 INS A 6.33E-08 1.16 [23,25,29]
rs4763879 12 9801431 12p13.31 A 6.45E-07 1.14 [24,29]
rs1701704 12 54698754 12q13.2 G 1.08E-30 1.35 [24-27,29]
rs10877012 12 56448352 CYP27B1 NA NA NA [54]
rs3184504 12 110368991 SH2B3 C 1.77E-21 0.79 [29]
rs9585056 13 98879767 GPR183 C 1.27E-03 1.09 [55]
rs1465788 14 68333352 14q24.1 T 1.79E-06 0.87 [29]
rs4900384 14 97568704 14q32.2 G 0.0972 1.05 [29]
rs941576 14 100375798 DLK1 G 9.33E-05 0.91 [56]
rs17574546 15 36689768 RASGRP1 C 3.19E-03 1.09 [57]
rs3825932 15 77022501 15q25.1 T 5.15E-05 0.90 [27,29]
rs2903692 16 11146284 16p13.13 A 4.21E-15 0.81 [23-25,27,29]
rs4788084 16 28447349 IL27 T 7.55E-04 0.92 [29]
rs7202877 16 73804746 16q23.1 G 1.84E-05 1.19 [29]
rs2290400 17 35319766 ORMDL3 T 3.55E-03 0.93 [29]
rs7221109 17 36023812 17q21.2 T 6.46E-04 0.92 [29]
rs478582 18 12825976 PTPN2 C 7.72E-04 0.92 [24,25,27,29]
rs763361 18 65682622 CD226 T 1.17E-04 1.10 [25]
rs2304256 19 10336652 TYK2 NA NA NA [56]
rs425105 19 51900321 19q13.32 C 5.51E-06 0.85 [29]
rs2281808 20 1558551 20p13 T 2.06E-06 0.88 [29]
rs9976767 21 42709459 UBASH3A G 1.69E-05 1.11 [28,29]
rs5753037 22 28911722 22q12.2 T 0.0164 1.06 [29]
rs229541 22 35921264 IL2RB A 3.67E-06 1.12 [27,29]
The list of known SNPs was collected from references cited in the references column and shown below. One SNP from each locus was chosen when multiple SNPs from
the same locus are known. NA in the effect allele, P-value, and OR column refers to SNPs that were not imputed in the discovery cohort. Positions shown are based on
Build 36 of the human genome.
doi:10.1371/journal.pgen.1002293.t002
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tional requirements and the Declaration of Helsinki Principles.
Samples
Cases in the discovery set were obtained from four publically
available resources and combined with those from a previous
publication for the meta-analysis. Samples descriptions areavailable
on dbgap (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap) for
the T1DGC (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs000180.v1.p1), GoKinD (http://www.ncbi.
nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000088.
v1.p1), and DCCT-EDIC (http://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?study_id=phs000086.v2.p1) patients. The
WTCCC sample information is available from [24]. Samples from
the T1D segment of the WTCCC were used as cases, while controls
were derived from the 1958 Birth Cohort, UK Blood Service,
Bipolar disorder, Coronary heart disease, Hypertension, and Type
2 Diabetes segments. The remaining cases used in the meta-analysis
were previously described [23].
The total number of individuals used in the meta-analysis
discovery set was 26,890 (9,934 cases/16,956 controls). The
replication set consisted of 1120 case-parent trios from the
T1DGC and those identified through pediatric diabetes clinics
in Canada. The replication set was identical to that used in
Hakonarson et al. with an extension of patients identified through
pediatric diabetes clinics in Montreal, Toronto, Ottawa, and
Winnipeg. All individuals were of Caucasian ancestry. A
breakdown of the number of samples in each cohort in the
discovery phase and a comparison with the numbers used in the
Barrett et al. meta-analysis are shown in Table 3 [29]. The minor
variation in the number of cases reflects that, despite using slight
differences in both quality control and methods for dealing with
population stratification, we have comparable numbers of cases
from this cohort remaining in our analysis. Primarily, this small
difference is due to the fact that we strictly accounted for
relatedness and duplicates within and across cohorts in this current
setting.
Power analysis
Power analysis was performed with the genetic analysis
calculator which can be found at (http://pngu.mgh.harvard.
edu/˜purcell/gpc/) [53]. Various assumption were made included
perfect LD between the causative variant and the markers that
were genotyped, an additive genetic model, a disease prevalence of
0.0033 and an alpha of 1610
25.
Genotyping, quality control, and imputation
Discovery samples from Philadelphia, Canada, T1DGC, and
DCCT-EDIC were genotyped on a mixture of the Illumina
HumanHap 550v1, 2, and 3, whereas samples from GoKinD and
WTCCC were genotyped on the Affymetrix 500 K Chip.
Sequenom iPlex was used to replicate the findings of the meta-
analysis in 1,120 affected offspring trios from the T1DGC and
from Canada.
All individuals needed an individual genotyping call rate greater
than 0.98 to be included in the analysis pre-imputation and
individuals were removed that showed evidence of cryptic
relatedness and duplication within and across cohorts using
identity-by-state. SNP quality control was performed on all
samples pre-imputation. SNPs were excluded from the analysis if
the minor allele was below 1%, the genotyping call rate was less
than 95%, or the Hardy Weinberg equilibrium P-value was less
than 0.00001.
To control for population stratification, Eigenstrat 3.0 was used
to compute the top 10 principal components of the individuals
genotyped on the Illumina SNP chips and the Affymetrix SNP
chips separately [37]. Individuals were removed from the analysis
if they were 6 standard deviations away from the mean of one of
the top 10 principal components. After controlling for population
stratification, the estimated lambda in the Affymetrix data was
1.11 and 1.17 in the Illumina data.
Mach 1.0 was used to impute ,2.54 millions SNPs from the
HapMap CEU panel for all individuals [39]. SNPs were excluded
after imputation if they had a minor allele frequency less than 0.01
and an r2 value less than 0.3.
Genome-wide association and meta-analysis
PLINK [38] was used to perform a logistic regression using the
10 principal components as covariates, T1D status as the outcome,
and in the case of the Affymetrix cohort, an extra dummy
covariate specifying WTCCC or GoKinD cohort membership.
Results from the logistic regression of 2,436,110 SNPs from the
Affymetrix samples and 2,062,307 SNPs from the Illumina
samples separately were combined using inverse-variance meta-
analysis in PLINK. A fixed effects meta-analysis was performed
and 53 SNPs were chosen for replication who had a fixed effects P-
value ,0.00001, a Cochran’s Q statistic P-value greater than 0.05
and were not previously known to be associated with type 1
diabetes. However one of the SNPs consistently failed during the
replication effort.
Supporting Information
Figure S1 Comparison of plot of power for previous and current
meta-analyses. a: Plot of power (y-axis) for variants from the
previously reported meta-analysis [29] with various allele frequen-
cies (x-axis) and relative risks. Plots assume disease prevalence of
0.0033, an additive genetic model, perfect LD between causative
variant and marker, and are shown for an alpha of 1610
25. b: Plot
of power (y-axis) in the current meta-analysis for variants with
various allele frequencies (x-axis) and relative risks. Plots assume
Table 3. A comparison of the number of samples used in each discovery cohort from the current meta-analysis and those used in
the previously reported meta-analysis [29] .
WTCCC GoKinD/NIMH DCCT-EDIC T1DGC CHOP-McGill Totals
Cases in Barrett et al meta-analysis 1,930 1,601 0 3,983 0 7,514
Controls in Barrett et al meta-analysis 3,342 1,704 0 3,999 0 9,045
Cases in current meta-analysis 1,920 1,491 1,363 4,029 1,131 9,934
Controls in current meta-analysis 10,308 0 0 0 6,648 16,956
doi:10.1371/journal.pgen.1002293.t003
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LD between causative variant and marker, and are shown for an
alpha of 1610
25.
(DOC)
Figure S2 Regional plot of the EFRB associated region. –
log10(P-values) are shown for all SNPs in the region and color of
circles indicates degree of LD with the most associated SNP in the
region. Recombination rate is overlaid on the figure and the
position with respect to genes is shown at the bottom.
(DOC)
Figure S3 Regional plot of the LMO7 associated region. –
log10(P-values) are shown for all SNPs in the region and color of
circles indicates degree of LD with the most associated SNP in the
region. Recombination rate is overlaid on the figure and the
position with respect to genes is shown at the bottom.
(DOC)
Figure S4 Regional plot of the LOC100128081 associated
region. –log10(P-values) are shown for all SNPs in the region
and color of circles indicates degree of LD with the most associated
SNP in the region. Recombination rate is overlaid on the figure
and the position with respect to genes is shown at the bottom.
(DOC)
Figure S5 Regional plot of the Chromosome 6 associated
region. –log10(P-values) are shown for all SNPs in the region and
color of circles indicates degree of LD with the most associated
SNP in the region. Recombination rate is overlaid on the figure
and the position with respect to genes is shown at the bottom.
(DOC)
Figure S6 Regional plot of the Chromosome 8 associated
region. –log10(P-values) are shown for all SNPs in the region and
color of circles indicates degree of LD with the most associated
SNP in the region. Recombination rate is overlaid on the figure
and the position with respect to genes is shown at the bottom.
(DOC)
Figure S7 Regional plot of the Chromosome 2 FOSL2 associated
region. –log10(P-values) are shown for all SNPs in the region and
color of circles indicates degree of LD with the most associated
SNP in the region. Recombination rate is overlaid on the figure
and the position with respect to genes is shown at the bottom.
(DOC)
Table S1 Discovery set P-values and odd ratios are shown for
strongest associated SNP in known T1D associated regions. The
list of known associated regions was collected from references cited
in the references column and shown below.
(DOC)
Table S2 P-values and odds ratios of discovery and replication
cohort are shown for all SNPs taken forward to replication stage.
Combined P-values are shown for all SNPs that had the same
direction of effect. P-values were combined using the Fishers
combined P-value method implemented in Haploview. NA refers
to a different direction of effect and the P-value was never
computed. One SNP, rs722988, which failed in the genotyping
assay is not shown.
(DOC)
Table S3 P-values for the six SNPs highlighted in Table 1
following adjustment for lambdas.
(DOC)
Text S1 Correlation outcomes of Eigenvectors with known
continental ancestry.
(DOC)
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